Next generation bioanalytical solutions
THE NK-92® ASSAY COMPANY
Brink Biologics, Inc. (BBI) is a NantKwest Inc. (NASDAQ: NK) affiliated biotechnology solutions company located in the prestigious Torrey Pines biotechnology science park in San Diego, CA.
KILLER CELLS - KILLER ASSAYS™
Natural Killer cell lines originating from a singular source, established in stable cultures under GLP & cGMP conditions and further modified into multiple panels of lines suitable for a range of laboratory testing applications.
NEUKOPANEL® CELL LINES
A standardized panel of CD16 expressing NK-92® cell lines, provides for the first time the means to establish a consistent, robust and reliable assay for assessment of ADCC activity.
Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92® Cells
NK-92® Cell Based Bioanalytical Solutions are the Key to Optimizing R&D and Commercial Product Development Efforts for Monoclonal Antibodies, Bi-Specifics and Related Biological Products SAN DIEGO--May 1, 2019-- Brink Biologics, Inc., a NantKwest,...
NantKwest Announces New haNK Natural Killer Cell Patent Issuance Further Expanding Intellectual Property Estate
New haNK and T-haNK Based Natural Killer Cell Therapy Programs to Transition to Human Clinical Trials in 2019CULVER CITY, CA - April 1, 2019 - NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced...
A NEUKOPANEL® OF NEUKOPLAST® NK-92 CELL LINES SUITABLE FOR A RANGE OF LABORATORY TESTING APPLICATIONSLearn More
The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.